285 related articles for article (PubMed ID: 36299454)
1. The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study.
Al-Mashhadi ZK; Viggers R; Fuglsang-Nielsen R; Vestergaard P; Gregersen S; Starup-Linde J
Front Endocrinol (Lausanne); 2022; 13():882998. PubMed ID: 36299454
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study.
Al-Mashhadi ZK; Viggers R; Starup-Linde J; Vestergaard P; Gregersen S
Front Endocrinol (Lausanne); 2022; 13():861422. PubMed ID: 36060970
[TBL] [Abstract][Full Text] [Related]
3. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
Hidayat K; Du X; Shi BM
Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
Xu L; Zheng XQ; Liao XX
Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
[TBL] [Abstract][Full Text] [Related]
5. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E
JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014
[TBL] [Abstract][Full Text] [Related]
6. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.
Bouzas C; Pastor R; Garcia S; Monserrat-Mesquida M; Martínez-González MÁ; Salas-Salvadó J; Corella D; Goday A; Martínez JA; Alonso-Gómez ÁM; Fernández-Barceló O; Vioque J; Romaguera D; Lopez-Miranda J; Estruch R; Tinahones FJ; Lapetra J; Serra-Majem L; Riquelme-Gallego B; Martín-Sánchez V; Pintó X; Delgado-Rodriguez M; Matía P; Vidal J; Cardenas-Salas JJ; Daimiel L; Ros E; Toledo E; Manzanares JM; Gonzalez-Monge I; Muñoz MÁ; Martinez-Urbistondo D; Tojal-Sierra L; Muñoz-Bravo C; Miralles-Gisbert S; Martin M; García-Ríos A; Castro-Barquero S; Fernández-García JC; Santos-Lozano JM; Basterra-Gortari FJ; Gutiérrez-Carrasquilla L; Guillem-Saiz P; Satorres A; Abete I; Sorto-Sanchez C; Díez-Espino J; Babio N; Fitó M; Tur JA
Biomed Pharmacother; 2023 May; 161():114561. PubMed ID: 36934556
[TBL] [Abstract][Full Text] [Related]
8. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like-peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study.
Zareini B; Sørensen KK; Pedersen-Bjergaard U; Loldrup Fosbøl E; Køber L; Torp-Pedersen C
J Diabetes; 2024 Jun; 16(6):e13560. PubMed ID: 38751369
[TBL] [Abstract][Full Text] [Related]
10. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
Newman TV; Munshi KD; Neilson LM; Good CB; Swart ECS; Huang Y; Henderson R; Parekh N
J Manag Care Spec Pharm; 2021 Apr; 27(4):435-443. PubMed ID: 33769857
[No Abstract] [Full Text] [Related]
11. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
Bea S; Jeong HE; Filion KB; Yu OH; Cho YM; Lee BH; Chang Y; Byrne CD; Shin JY
JAMA Netw Open; 2023 Dec; 6(12):e2349856. PubMed ID: 38153732
[TBL] [Abstract][Full Text] [Related]
13. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
Fu EL; Mastrorilli J; Bykov K; Wexler DJ; Cervone A; Lin KJ; Patorno E; Paik JM
Kidney Int; 2024 Mar; 105(3):618-628. PubMed ID: 38101515
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.
Tsai HR; Lin YJ; Yeh JI; Huang YC; Liu PP; Peng CC; Hsu JY; Lee YC; Loh CH; Lin SM; Huang HK
Diabetes Metab Res Rev; 2024 Feb; 40(2):e3739. PubMed ID: 37862117
[TBL] [Abstract][Full Text] [Related]
15. Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice.
Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2020 Jun; 19(1):74. PubMed ID: 32522260
[TBL] [Abstract][Full Text] [Related]
16. Discrepancies in type of first major osteoporotic fracture and anti-osteoporotic therapy in elderly people with type 2 diabetes mellitus: A retrospective Danish cohort study.
Viggers R; Starup-Linde J; Vestergaard P
Bone; 2023 Jun; 171():116745. PubMed ID: 36965654
[TBL] [Abstract][Full Text] [Related]
17. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.
Zhuo M; Paik JM; Wexler DJ; Bonventre JV; Kim SC; Patorno E
Am J Kidney Dis; 2022 Jun; 79(6):858-867.e1. PubMed ID: 34762974
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
Hou WH; Chang KC; Li CY; Ou HT
Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544
[TBL] [Abstract][Full Text] [Related]
20. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
